Institutional members access full text with Ovid®

Share this article on:

Risk of Heart-Related Death From Gout Medication

Aschenbrenner, Diane, S., MS, RN

AJN The American Journal of Nursing: March 2018 - Volume 118 - Issue 3 - p 23
doi: 10.1097/01.NAJ.0000530934.96489.f0
Drug Watch
  • Preliminary results from a clinical safety trial of the gout medication febuxostat (Uloric) indicate that, when compared with allopurinol, the standard gout treatment, febuxostat increases the risk of heart-related deaths.
  • The Food and Drug Administration will provide additional information after the final trial results are submitted and analyzed.

Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: daschenbrenner@ndm.edu.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.